9 assets in Diffuse Astrocytoma

Therapeutic assets addressing Diffuse Astrocytoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Dabrafenib Diffuse Astrocytoma	Novartis Pharmaceuticals	P4	BB (65)
Trametinib Diffuse Astrocytoma	Novartis Pharmaceuticals	P4	BB (65)
Atezolizumab Diffuse Astrocytoma	National Cancer Institute (NCI)	P2	CCC (53)
Pemigatinib Diffuse Astrocytoma	Incyte Corporation	P2	CCC (53)
Tocilizumab Diffuse Astrocytoma	National Cancer Institute (NCI)	P2	CCC (53)
Eflornithine Diffuse Astrocytoma	Mayo Clinic	P1/2	CCC (48)
Retifanlimab Diffuse Astrocytoma	Mayo Clinic	P1/2	CCC (48)
Onc 206 Diffuse Astrocytoma	Jazz Pharmaceuticals	P1	CC (43)
Vipivotide Tetraxetan Diffuse Astrocytoma	Memorial Sloan Kettering Cancer Center	P1	CC (43)